Drug Profile
Budesonide orodispersible tablets - Dr Falk Pharma
Alternative Names: BUET; JorvezaLatest Information Update: 19 Dec 2021
Price :
$50
*
At a glance
- Originator Dr Falk Pharma
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antivirals; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Eosinophilic oesophagitis
- Phase III Graft-versus-host disease
- Phase II Gastrointestinal disorders
Most Recent Events
- 07 Oct 2021 Dr Falk Pharma completes a phase III trial for Eosinophilic oesophagitis in Belgium, UK, Germany, Netherlands, Denmark, Spain, Italy (PO) in December 2020 (EudraCT2014-001485-99) (NCT02493335)
- 26 Apr 2021 Phase-III clinical trials in Eosinophilic oesophagitis in Germany (PO) (EudraCT2020-001314-37)
- 14 Jan 2021 Dr Falk Pharma initiates a phase III trial for Eosinophilic oesophagitis in Germany (PO) (EudraCT2017-003516-39)